Immunotherapy/TKI Combinations in Advanced RCC

Dr Singer on the Efficacy of IO/TKI Doublets in Advanced RCCПодробнее

Toxicity Management in Advanced Renal Cell Carcinoma: Immunotherapy InsightsПодробнее

Dr Abhishek Raj | Role of Immunotherapy in management of advanced RCCПодробнее

UROwebinar: Management of Metastatic kidney cancerПодробнее

Selecting and Sequencing Targeted and Immunotherapy Regimens for Patients With RCCПодробнее

Comparing Combination Treatment Approaches in Front-Line Advanced RCCПодробнее

Advanced Kidney Cancer: What the Urologist Needs to KnowПодробнее

Immunotherapy-based combinations for advanced/metastatic renal cell carcinoma: ASCO GU 2023Подробнее

Dr Deepak Koppaka | Advanced RCC Personalizing Treatment in the ERA of ImmunotherapyПодробнее

Immunotherapy Combinations Improve Survival in Advanced Renal Cell CarcinomaПодробнее

Managing Advanced Renal Cell Carcinoma - QuinnПодробнее

Dr. Grigg on Immunotherapy/TKI Combinations in RCCПодробнее

Immunotherapy in Renal Cell CarcinomaПодробнее

Favorable-Risk RCC: Frontline VEGF TKI/IO CombinationsПодробнее

Dr. McDermott on TKI/Immunotherapy Combinations in RCCПодробнее

New and Emerging Systemic Treatment Options for Metastatic Kidney Cancer Scott S. Tykodi, M.D., PhD.Подробнее

Dr. Amin on Toxicities With Immunotherapy/TKI Combinations in RCCПодробнее

Michael B. Atkins, MD, on selecting I-O and TKI combinations for the treatment of 1st line RCCПодробнее

Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCCПодробнее